Eliglustat substrate reduction therapy in children with Gaucher disease type 1
ImportanceGaucher disease (GD) is a rare lysosomal storage disorder with limited treatment options for pediatric patients. Oral substrate reduction therapy (SRT) with eliglustat offers a potential alternative, particularly for those with barriers to enzyme replacement therapy (ERT).ObjectiveEvaluate...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1543136/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850079133459021824 |
|---|---|
| author | Noor Ul Ain Armaan Saith Audrey Ruan Ruhua Yang Aaron Burton Pramod K. Mistry Pramod K. Mistry |
| author_facet | Noor Ul Ain Armaan Saith Audrey Ruan Ruhua Yang Aaron Burton Pramod K. Mistry Pramod K. Mistry |
| author_sort | Noor Ul Ain |
| collection | DOAJ |
| description | ImportanceGaucher disease (GD) is a rare lysosomal storage disorder with limited treatment options for pediatric patients. Oral substrate reduction therapy (SRT) with eliglustat offers a potential alternative, particularly for those with barriers to enzyme replacement therapy (ERT).ObjectiveEvaluate the safety and efficacy of eliglustat SRT in pediatric patients with type 1 Gaucher disease (GD1), both as initial therapy and as a switch from intravenous ERT.DesignA prospective case series was conducted from 2017 to 2024.SettingYale's National Gaucher Disease Treatment Center, New Haven, CT, United States.ParticipantsFourteen pediatric GD1 patients with significant barriers to receiving ERT.InterventionEliglustat SRT was dosed pharmacogenomically based on CYP2D6 metabolizer status.Primary outcomes and measuresPrimary outcomes included safety and efficacy in reversing indicators of disease activity. Secondary outcomes involved changes in patient and parent-reported quality of life, assessed using PROMIS questionnaires.ResultsEliglustat was initiated at a mean age of 12.5 years (range: 6–17 years) and administered for a mean duration of 3.6 years (range: 1–7 years). All patients remained on treatment and exhibited sustained reductions in glucosylsphingosine (GlcSph) levels compared to baseline (p = 0.005). Other disease indicators demonstrated corresponding improvements. Adverse effects were limited to transient gastroesophageal reflux in 3/14 patients (21%). Serial electrocardiograms (EKGs) were normal. Growth and developmental milestones were appropriate for age in all patients. Patients and their parents reported a global improvement in quality of life.ConclusionsEliglustat demonstrated significant clinical benefits in pediatric GD1 patients, as evidenced by reductions in GlcSph levels and other disease indicators. The therapy showed a favorable safety profile comparable to that observed in adults. These findings suggest eliglustat is a promising therapeutic option for pediatric GD1 patients, providing an effective alternative to ERT. |
| format | Article |
| id | doaj-art-4474ec865b4e4b17b1f1d5378235a231 |
| institution | DOAJ |
| issn | 2296-2360 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj-art-4474ec865b4e4b17b1f1d5378235a2312025-08-20T02:45:19ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-02-011310.3389/fped.2025.15431361543136Eliglustat substrate reduction therapy in children with Gaucher disease type 1Noor Ul Ain0Armaan Saith1Audrey Ruan2Ruhua Yang3Aaron Burton4Pramod K. Mistry5Pramod K. Mistry6Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United StatesDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, United StatesDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, United StatesDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, United StatesSpecialty Pharmacy, Yale New Haven Hospital, New Haven, CT, United StatesDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, United StatesDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, United StatesImportanceGaucher disease (GD) is a rare lysosomal storage disorder with limited treatment options for pediatric patients. Oral substrate reduction therapy (SRT) with eliglustat offers a potential alternative, particularly for those with barriers to enzyme replacement therapy (ERT).ObjectiveEvaluate the safety and efficacy of eliglustat SRT in pediatric patients with type 1 Gaucher disease (GD1), both as initial therapy and as a switch from intravenous ERT.DesignA prospective case series was conducted from 2017 to 2024.SettingYale's National Gaucher Disease Treatment Center, New Haven, CT, United States.ParticipantsFourteen pediatric GD1 patients with significant barriers to receiving ERT.InterventionEliglustat SRT was dosed pharmacogenomically based on CYP2D6 metabolizer status.Primary outcomes and measuresPrimary outcomes included safety and efficacy in reversing indicators of disease activity. Secondary outcomes involved changes in patient and parent-reported quality of life, assessed using PROMIS questionnaires.ResultsEliglustat was initiated at a mean age of 12.5 years (range: 6–17 years) and administered for a mean duration of 3.6 years (range: 1–7 years). All patients remained on treatment and exhibited sustained reductions in glucosylsphingosine (GlcSph) levels compared to baseline (p = 0.005). Other disease indicators demonstrated corresponding improvements. Adverse effects were limited to transient gastroesophageal reflux in 3/14 patients (21%). Serial electrocardiograms (EKGs) were normal. Growth and developmental milestones were appropriate for age in all patients. Patients and their parents reported a global improvement in quality of life.ConclusionsEliglustat demonstrated significant clinical benefits in pediatric GD1 patients, as evidenced by reductions in GlcSph levels and other disease indicators. The therapy showed a favorable safety profile comparable to that observed in adults. These findings suggest eliglustat is a promising therapeutic option for pediatric GD1 patients, providing an effective alternative to ERT.https://www.frontiersin.org/articles/10.3389/fped.2025.1543136/fullGaucher disease (GD)precision medicinesubstrate reduction therapy (SRT)eliglustatlysosomal storage disease (LSD) |
| spellingShingle | Noor Ul Ain Armaan Saith Audrey Ruan Ruhua Yang Aaron Burton Pramod K. Mistry Pramod K. Mistry Eliglustat substrate reduction therapy in children with Gaucher disease type 1 Frontiers in Pediatrics Gaucher disease (GD) precision medicine substrate reduction therapy (SRT) eliglustat lysosomal storage disease (LSD) |
| title | Eliglustat substrate reduction therapy in children with Gaucher disease type 1 |
| title_full | Eliglustat substrate reduction therapy in children with Gaucher disease type 1 |
| title_fullStr | Eliglustat substrate reduction therapy in children with Gaucher disease type 1 |
| title_full_unstemmed | Eliglustat substrate reduction therapy in children with Gaucher disease type 1 |
| title_short | Eliglustat substrate reduction therapy in children with Gaucher disease type 1 |
| title_sort | eliglustat substrate reduction therapy in children with gaucher disease type 1 |
| topic | Gaucher disease (GD) precision medicine substrate reduction therapy (SRT) eliglustat lysosomal storage disease (LSD) |
| url | https://www.frontiersin.org/articles/10.3389/fped.2025.1543136/full |
| work_keys_str_mv | AT noorulain eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT armaansaith eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT audreyruan eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT ruhuayang eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT aaronburton eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT pramodkmistry eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 AT pramodkmistry eliglustatsubstratereductiontherapyinchildrenwithgaucherdiseasetype1 |